FDA Green Lights Avalon GloboCare's KetoAir Breathalyzer

Core Viewpoint - Avalon GloboCare Corp's stock is experiencing a decline without any specific news to justify the movement, despite the recent FDA registration renewal for its KetoAir device [1] Group 1: Product Overview - The KetoAir device is a handheld breathalyzer that measures breath acetone concentration (BrAce), a biomarker linked to fat metabolism and nutritional ketosis [2] - Utilizing nano-sensor technology, KetoAir offers real-time, non-invasive insights into metabolic states through breath analysis, targeting individuals on ketogenic diets for various purposes [2] - The device is compatible with both iOS and Android smartphones, with applications available on major app stores [3] Group 2: Market Strategy - Avalon GloboCare plans to launch the KetoAir device in both B2B and B2C markets, enhancing marketing and distribution through its subsidiary, Avalon Quantum AI, LLC [3] - Marketing efforts for the device are set to begin in the second quarter of 2026, which is viewed as a significant milestone for the company [4] Group 3: Stock Performance - The stock is currently trading 31.1% below its 20-day simple moving average (SMA) and 55.5% below its 100-day SMA, indicating strong bearish momentum [5] - Over the past year, shares have decreased by 70.51%, and the stock is closer to its 52-week lows than highs [5] - As of the latest publication, shares were down 23.64% at $0.84, marking a new 52-week low [7]